Taken together, these data indicate that DIVA2 boosts specific CD8+ T cell generation that converts to effective primary and memory responses that are highly functional in clearing MC38mOVA tumor cells in vivo in a prophylactic tumor vaccination setting. The gene discussed is CD8A; the disease is neoplasm.